News

RIVANNA® Announces Alliance With Tri-anim Health Services

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with Tri-anim Health Services, a specialty distributor of respiratory, anesthesia, and critical-care supplies, to represent and distribute the Accuro® portfolio of products in the United States.
RIVANNA announced a partnership with Tri-anim Health Services

Tri-anim is a natural distribution choice for RIVANNA as they provide effective and efficient patient care solutions, including innovative and proven specialty anesthesia products and consumables to support the vital role of the anesthesia provider.

Will Mauldin, Ph.D., co-founder, and CEO of RIVANNA, commented, “We worked together to establish this strategic partnership, and are excited to begin an alliance with Tri-anim due in part to their specialty anesthesia focus and clinical expertise. This milestone demonstrates an increasing opportunity for Accuro sales in the anesthesia market, and we are pleased to gain momentum across the United States. Accuro’s increased national expansion and continuing worldwide market adoption indicate RIVANNA’s success and the progression of our ongoing mission to elevate the standard of care.”

The Accuro spinal navigation system is designed to improve the efficiency of spinal needle guidance procedures using groundbreaking technology, including Multi-Frequency BoneEnhance® Image Reconstruction, which provides enhanced visualization of lumbar and thoracic bony anatomy, and SpineNav3D™AI-Based Spine Recognition, which provides automated identification of spinal midline, epidural space, and depth during lumber neuraxial anesthesia. This technology also supports real-time thoracic paramedian neuraxial procedures and prescribes a “needle-track” towards the interlaminar space. Relying on automated SpineNav3D™ technology, Accuro enables users with even minimal ultrasound experience to navigate the lumbar and thoracic spine and identify relevant landmarks used to compute, visualize and pinpoint the optimal needle insertion point.

Tom Metcalf, President of Tri-anim Health Services, said, “The Tri-anim team is thrilled to introduce this groundbreaking technology to an expanding market supporting spinal needle guidance procedures in the U.S., as it underpins Tri-anim’s vision to offer the most effective products and solutions to our customers. The Accuro is clinically proven to increase first-attempt success rates, especially with challenging patient anatomy, and will help anesthesia providers improve their efficiency and elevate their standard of care.”

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and